Navigation Links
Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
Date:4/15/2008

idered protective.

"The Iomai immunostimulant patch has the potential to change how we react to an influenza pandemic, and we will move ahead quickly with the development of this technology," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "Based on the data from this new Phase 2 study, Iomai and HHS will evaluate whether to proceed next with a pivotal Phase 3 trial. Our work would not be possible without the enthusiasm and commitment of HHS throughout the process."

This research is being funded under a $128 million contract awarded by HHS in January 2007. Of this amount, $14.5 million was targeted toward completion of the Phase 1/2 study. Using the results of this trial, Iomai is currently working with HHS to refine the clinical development plan and budget for the new Phase 2 trial going forward.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looki
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 According to the ... Pre-packed, Analytical, Preparative), by Material (Metal, Glass, Plastic), by ... Forecast to 2018", published by MarketsandMarkets, the Chiral Chromatography ... is poised to grow at a CAGR of 5.2% ... Browse 90 market data tables and 15 ...
(Date:9/2/2014)... ALISO VIEJO, Calif. , Sept. 2, 2014  Avanir ... company management will present an overview of the company at ... York . , Presentation date: Tuesday September ... A live webcast and 30-day archive of ... About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, ...
(Date:9/2/2014)... 2014  EMD Serono, Inc., a subsidiary of Merck ... that Drew Young has joined the company ... capacity, he will be responsible for leading the strategic ... future products.   Bringing more than 20 years ... efforts at pharmaceutical and biotech companies, Mr. Young comes ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
(Date:9/2/2014)... (PRWEB) September 03, 2014 Recently, BambooIndustry.com, ... its new range of strand woven bamboo floors ... more clients and show its appreciation to the frequent ... products. , In addition to strand woven floors, ... clients, including hand scraped floors, click strand woven floors, ...
(Date:9/2/2014)... Atlanta, Ga. (PRWEB) September 02, 2014 ... hosted by, respectively, top-industry professionals Carey Lewis ... each person auditioning, seeking those who have the desire ... chosen for a callback, performers could be invited to ... SHINE convention. , Charlotte, NC – Saturday, Sept. 6, ...
(Date:9/2/2014)... 2014 The Wm. Jennings Bryan Dorn Veterans ... town hall meeting for Veterans and their families on September ... fair to provide Veterans with valuable healthcare and benefit information,” ... will provide a forum where we can gather important input ... outreach fair will be held 4:45 p.m. to 5:45 p.m. ...
(Date:9/2/2014)... In a large population-based study of randomly selected ... impairment (MCI) occurred twice more often in individuals ... strong association was only observed in middle-aged participants ... the association vanished. This study is published in ... The concept of MCI describes an intermediate state ...
(Date:9/2/2014)... Operators in the Community Services industry ... care and counsel for those in need. In 2014-15, ... derive $39.4 billion in revenue, which includes a combination ... five years through 2014-15, the subdivision is forecast to ... of 4.1% in 2014-15. , As the population ages ...
Breaking Medicine News(10 mins):Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Using tiny gold particles embedded with dyes, researchers have ... of a living animal. These tools may allow doctors ... , Studded with antibody fragments called ScFv peptides that ... after their injection into a mouse. When illuminated with ...
... simple steps can help you cope , , SATURDAY, Dec. 22 ... of joy and celebration for many, it can trigger holiday ... to holiday blues, there are things you can do to ... Mood Disorders Program at the Jefferson Medical College of Thomas ...
... Kansas Hospital Offers Tips to Guard Against Influenza as ... ... While it may be too late to,purchase certain must-have gifts ... shot. The World Health Organization (WHO) and,National Respiratory and Enteric Virus ...
... PCYC ) today announced that it has received a ... for the company,s,new drug application (NDA) for Xcytrin(R) (motexafin ... (NSCLC) patients with brain,metastases. The NDA for use of ... filed with the FDA in April 2007., According ...
... indications than any other ... drug-eluting stent, ... announced today that its TAXUS(R) Liberte(TM),paclitaxel-eluting coronary stent system has received ... submitted,data showing the TAXUS Liberte stent has benefited diabetic patients with,coronary ...
... considered, protected, HARRISBURG, Pa., Dec. 21 To ... Joel,Ario today announced that the Insurance Department will hold ... the proposed consolidation of,Independence Blue Cross and Highmark Inc., ... would be protected in,any transaction of this type, so ...
Cached Medicine News:Health News:Gold nanoparticle probes may allow earlier cancer detection 2Health News:Gold nanoparticle probes may allow earlier cancer detection 3Health News:Maintaining Routine Can Chase Holiday Blues Away 2Health News:Attention Last-Minute Shoppers: Flu Shots Still Available 2Health News:Attention Last-Minute Shoppers: Flu Shots Still Available 3Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 2Health News:Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 2Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 3Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 4Health News:TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients 5Health News:Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross 2
... Chrome-plated metal frames ... ensures optimal cleanliness and ... stools come with user-friendly ... height adjustment. Fixed footring ...
... The ideal modular cleanroom for ... applications that require cleanliness (to Class ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Inquire...
Medicine Products: